神经心理学BrainAge:一个转换从轻度认知障碍到阿尔茨海默病的生物标志物
Jorge Garcia Condado1,2, Jesus M Cortes1,3,4,
1Computational Neuroimaging Laboratory Biobizkaia Health Research Institute Barakaldo, Bizkaia Spain.
Alzheimer's & dementia (Amsterdam, Netherlands)
|November 1, 2023
概括
使用神经心理测试的BrainAge模型有效地区分了稳定的轻度认知障碍 (sMCI) 与渐进的MCI (pMCI),优于神经成像方法. 这种BrainAge三角形显示为预测阿尔茨海默病进展的生物标志物具有前途.
科学领域:
- 神经科学是一个神经科学.
- 认知科学 认知科学
- 生物标志物发现发现
背景情况:
- 虽然BrainAge模型很强大,但由于数据的变化,它们面临着可复制性挑战.
- 神经心理测试为BrainAge建模提供了一个潜在的替代方案,特别是用于区分MCI亚型.
研究的目的:
- 评估BrainAge模型的有效性,使用神经心理测试与神经影像测试来区分稳定轻度认知障碍 (sMCI) 和渐进轻度认知障碍 (pMCI).
- 评估BrainAge delta对转化为阿尔茨海默病 (AD) 的时间的预测值.
主要方法:
- 开发了使用健康对照者的线性回归 BrainAge 模型,单独分析神经心理测试和神经成像特征.
- 计算的BrainAge delta (预测年龄 - 时间表年龄) 作为分类的度量.
- 使用接收机操作特征 (ROC) 曲线分析进行性能评估.
主要成果:
- 基于神经心理测试的BrainAge模型在sMCI与pMCI分类的ROC曲线 (0.91) 下实现了显著更高的交叉验证区域,与神经成像模型 (0.68) 相比.
- 结合神经心理和神经成像特征并没有比单独的神经心理测试提高分类准确性.
- 来自两种模型类型的BrainAge delta与转化为AD的时间相关.
结论:
- 从神经心理测试中得出的BrainAge delta是区分sMCI和pMCI的强有力的生物标志物.
- 这种方法有可能用于研究其他神经和精神疾病.
相关概念视频
Alzheimer's Disease: Overview
498
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
498
Dementia
120
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
120
Alzheimer's Disease: Treatment
197
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
197
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
130
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
130


